Bb Biotech AG BB BIOTECH ORD SHS
Bb Biotech AG BB BIOTECH ORD SHS/ CH0038389992 /
0JYO
16/08/2024 16:40:02
|
Chg.
+0.50
|
Volume |
Bid17:40:06 |
Ask17:40:06 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
40.40CHF
|
+1.25%
|
2,984 Turnover: 120,747.25 |
-Bid Size: - |
-Ask Size: - |
2.22 bill.CHF |
4.98% |
- |
Business description
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world’s largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech’s investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
Management board & Supervisory board
CEO |
Dr. Daniel Koller |
Management board |
Dr. Thomas von Planta, Laura Hamill, Dr. Pearl Huang, Prof. Dr. Mads Krogsgaard Thomsen, Camilla Soenderby |
Supervisory board |
Dr. Clive Meanwell |
Company data
Name: |
BB Biotech AG |
Address: |
Schwertstraße 6,CH-8200 Schaffhausen/Schweiz |
Phone: |
+41-52-624-0845 |
Fax: |
- |
E-mail: |
info@bbbiotech.com
|
Internet: |
www.bbbiotech.com |
Industry: |
Financial |
Sector: |
Specialty Finance |
Sub sector: |
Diversified Financial |
End of financial year: |
31/12 |
Free Float: |
97.00% |
IPO date: |
10/12/1997 |
Investor relations
Name: |
Dr. Silvia Siegfried-Schanz |
IR phone: |
+41-44-267-7266 |
IR Fax: |
- |
IR e-mail: |
ssc@bellevue.ch
|
Company calendar
CW 43 | 25/10/2024
Interim Report 3rd Quarter/9 Months
|
Main Shareholders
Freefloat |
|
96.47% |
Lazard Asset Management LLC, New York, USA |
|
3.53% |